Mérieux Equity names Jean-Guillaume Lafay as operating partner
- He will support MxEP’s portfolio companies in leadership and governance, HR, quality, traceability, processes and more
- MxEP is an investment firm specialising in the healthcare sector
- The firm It has over €1.5 billion in assets under management
Mérieux Equity Partners (MxEP) has appointed Jean-Guillaume Lafay as operating partner, building on the development of the firm’s innovation activity.
Lafay has expertise in the fields of therapeutic platforms and life science. He co-founded Mablink in 2018 and served as CEO. MxEP was an early investor in Mablink and remained a shareholder until it was sold to Eli Lilly in 2023. He also founded four other companies focused on healthcare innovation.
In this new role, he will support MxEP’s portfolio companies in areas such as leadership and governance, HR, quality, traceability, processes and more. He will also be a key contributor to the investment process of the Innovation funds managed by MxEP.
“We have a high ambition for our Innovation activity, as we embark a new fundraising, and Jean-Guillaume Lafay will be key in helping us achieve these goals,” said Valérie Calenda, managing partner – innovation at MxEP, in a statement.
MxEP is an investment firm specializing in the healthcare sector. It has over €1.5 billion in assets under management through two dedicated strategies: Innovation and Buyout. It is based in Lyon and Paris.
MxEP’s innovation team has completed 15 investments in early stage healthcare companies since the launch of OMX Europe, including Mablink, Acusurgical, SeqOne, CellEasy and Cairdac. OMX Europe already completed 2 exits, including Mablink.
